Structure Therapeutics, Inc. share price logo

Structure Therapeutics, Inc. Share Price

NASDAQ: GPCR

Mid Cap

$46.01

-0.19

(-0.41%)

as on

Structure Therapeutics, Inc. Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $44.77
    $46.54
    downward going graph

    2.70%

    Downside

    1.15%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $13.22
    $94.90
    downward going graph

    71.27%

    Downside

    106.26%

    Upside

    downward going graph

Structure Therapeutics, Inc. share price movements today

Previous Close
$46.20
Open
$46.10
Volume
1.6M
Day's Low - High
$44.77 - $46.54
52 Week Low - High
$13.22 - $94.90

Structure Therapeutics, Inc. Historical Returns

1 Month Return
-27.09 %
3 Month Return
-32.81 %
1 Year Return
+ 132.27 %
3 Year Return
+ 116.5 %
5 Year Return
0 %

Structure Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Structure Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.3B

EPS (TTM)

-1.4827

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-185.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-11.86%

Structure Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Structure Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Structure Therapeutics, Inc. image
Structure Therapeutics, Inc.
BUY$3.3BNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.5B132.92%140.848.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.2B101.77%29.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.8BNA112.585.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.0B54.69%18.2531.41%

Stock Returns calculator for Structure Therapeutics, Inc. Stock including INR - Dollar returns

The Structure Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Structure Therapeutics, Inc. investment value today

Current value as on today

₹2,43,354

Returns

₹1,43,354

(+143.35%)

Returns from Structure Therapeutics, Inc. Stock

₹1,32,726 (+132.73%)

Dollar Returns*

₹10,628 (+10.63%)

Analyst Recommendation on Structure Therapeutics, Inc. Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Structure Therapeutics, Inc.. Average target price of $109

Structure Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Structure Therapeutics, Inc..

What analysts predicted

57.79%UPSIDE

Target Price

$109

Current Price

$46.01

Analyzed by

14 Analysts

Target

$109.00

Structure Therapeutics, Inc. target price $109, a slight upside of 57.79% compared to current price of $46.01. According to 14 analysts rating.

Structure Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Structure Therapeutics, Inc. Stock has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-35% versus previous 30 day period

Structure Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
1
-
-
-
1
-
-
-
-
Gross Profit
0
1
0
0
0
0
0
0
-
-
Operating Income
-26
-30
-32
-33
-45
-47
-56
-70
-73
23
EBITDA
-26
-30
-31
-33
-45
-46
-56
-70
-65
33
Interest Expense
2
9
6
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-23
-24
-26
-25
-33
-36
-46
-61
-65
33
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-23
-24
-26
-26
-33
-36
-46
-61
-65
33
Net Profit Margin
0.00%
-1842.38%
0.00%
0.00%
0.00%
-2047.86%
0.00%
0.00%
0.00%
0.00%

Structure Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
Gross Profit
0
0
0
0
-2
-3
Operating Income
0
-37
-52
-102
-158
-287
EBITDA
0
-37
-52
-102
-157
-136
Interest Expense
0
0
1
13
-
-
Depreciation
-
0
0
0
0
1
Income Before Tax
0
-37
-51
-89
-122
-140
Income Tax Expense
0
0
0
0
0
0
Net Income
0
-40
-51
-89
-122
-141
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Structure Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-24
-26
-26
-33
-36
-46
-61
-65
33
Operating Cash Flow
-21
-34
-26
-19
-36
-52
-54
-50
-64
Investing Cash Flow
-180
1
-204
-189
33
34
48
-49
56
Financing Cash Flow
281
0
514
0
0
0
0
56
704
Change in Cash
79
-31
283
-209
-2
-17
-5
-44
696

Structure Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-38
-51
-89
-122
-141
Operating Cash Flow
-32
-46
-79
-116
-222
Investing Cash Flow
17
-62
-268
-358
89
Financing Cash Flow
103
29
451
515
762
Change in Cash
88
-79
103
39
630

Structure Therapeutics, Inc. News & Key Events

  • img

    Today's Timeline - 08 December

    Mon, 11:05 PM

    -

    Structure Therapeutics' obesity pill shows up to 11% weight loss after 36 weeks, boosting shares nearly double.

    Tue, 02:31 AM

    -

    Structure Therapeutics announces proposed $500 million public offering of American Depositary Shares and pre-funded warrants.

Insights on Structure Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GPCR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, GPCR has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, GPCR stock has moved down by -27.1%

About Structure Therapeutics, Inc.

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
OrganisationStructure Therapeutics, Inc.
Headquarters601 Gateway Boulevard, South San Francisco, CA, United States, 94080
IndustryHealthcare
CEODr. Raymond C. Stevens Ph.D.
E-voting on sharesClick here to vote

Key Management of Structure Therapeutics, Inc.

Name

Title

Mr. Bob Gatmaitan

Senior Vice President of People

Dr. Hui Lei Ph.D.

Senior Vice President of Chemistry

Ms. Lani Ibarra

Senior Vice President of Clinical Development Operations

Dr. Blai Coll M.D., Ph.D.

Chief Medical Officer

Mr. Jun S. Yoon

Co- Founder, CFO & Secretary

Dr. Yingli Ma Ph.D.

Chief Technology Officer

Mr. Tony Peng

Senior Vice President of Legal

Dr. Raymond C. Stevens Ph.D.

CEO & Director

Dr. Xichen Lin Ph.D.

Chief Scientific Officer & GM of Structure Shanghai

Dr. Fang Zhang Ph.D.

Executive VP & Head of Biology

FAQs

What is Structure Therapeutics, Inc. share price today?

Structure Therapeutics, Inc. share price today is $46.01 as on at the close of the market. Structure Therapeutics, Inc. share today touched a day high of $46.54 and a low of $44.77.

What is the 52 week high and 52 week low for Structure Therapeutics, Inc. share?

Structure Therapeutics, Inc. share touched a 52 week high of $94.9 on and a 52 week low of $13.22 on . Structure Therapeutics, Inc. stock price today i.e. is closed at $46.01,which is 51.52% down from its 52 week high and 248.03% up from its 52 week low.

What is Structure Therapeutics, Inc.'s market capitalisation today?

Structure Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Structure Therapeutics, Inc. Stock (GPCR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Structure Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Structure Therapeutics, Inc. Shares that will get you 0.0326 shares as per Structure Therapeutics, Inc. share price of $46.01 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Structure Therapeutics, Inc. Stock (GPCR) from India?

Indian investors can start investing in Structure Therapeutics, Inc. (GPCR) shares with as little as ₹94.63 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.30 in Structure Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Structure Therapeutics, Inc. share’s latest price of $46.01 as on March 28, 2026 at 1:29 am IST, you will get 0.2173 shares of Structure Therapeutics, Inc.. Learn more about fractional shares .